Spine

Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Retrieved on: 
Thursday, April 18, 2024

Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Key Points: 


Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Infections after surgery are more likely due to bacteria already on your skin than from microbes in the hospital − new research

Retrieved on: 
Wednesday, April 10, 2024

Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.

Key Points: 
  • Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.
  • We show that many surgical site infections after spinal surgery are caused by microbes that are already on the patient’s skin.

Surgical infections are a persistent problem

  • Among the different types of heath care-associated infections, surgical site infections stand out as particularly problematic.
  • A 2013 study found that surgical site infections contribute the most to the annual costs of hospital-acquired infections, totaling over 33% of the US$9.8 billion spent annually.
  • Still, surgical site infections occur following about 1 in 30 procedures, typically with no explanation.
  • While rates of many other medical complications have shown steady improvement over time, data from the Agency for Healthcare Research and Quality and the Centers for Disease Control and Prevention show that the problem of surgical site infection is not getting better.

BYOB (Bring your own bacteria)

  • Prior studies on surgical site infection have been limited to a single species of bacteria and used older genetic analysis methods.
  • But new technologies have opened the door to studying all types of bacteria and testing their antibiotic resistance genes simultaneously.
  • Over a one-year period, we sampled the bacteria living in the nose, skin and stool of over 200 patients before surgery.
  • In fact, 86% of the bacteria causing infections after spine surgery were genetically matched to bacteria a patient carried before surgery.
  • That number is remarkably close to estimates from earlier studies using older genetic techniques focused on Staphylococcus aureus.
  • They likely acquired these antibiotic-resistant microbes through prior antibiotic exposure, consumer products or routine community contact.

Preventing surgical infections

  • At face value, our results may seem intuitive – surgical wound infections come from bacteria that hang out around that part of the body.
  • If the most likely source of surgical infection – the patient’s microbiome – is known in advance, this presents medical teams with an opportunity to protect against it prior to a scheduled procedure.
  • The fact that most infections don’t actually start with sources in the hospital is probably a testament to the efficacy of these protocols.


Dustin Long receives funding from the National Institutes of Health. Dr Bryson-Cahn receives funding from the Gordon and Berry Moore Foundation and is the co-medical director for Alaska Airlines.

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Retrieved on: 
Monday, April 8, 2024

Miranda Toledano, CEO of Entera, commented, “We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR.

Key Points: 
  • Miranda Toledano, CEO of Entera, commented, “We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR.
  • We believe EB613 addresses the current treatment gap in osteoporosis as the first oral, osteoanabolic (bone building) once-daily tablet treatment due to its unique format and potential dual mode of action.
  • The highest EB613 oral PTH tablet dose (2.5 mg), produced an increase in markers of bone formation while simultaneously decreasing the markers of bone breakdown.
  • The 2.5 mg oral PTH tablet dose was well tolerated when patients were instructed to titrate up to the full dose.

Sacks Parente Golf Expands its Newton Golf Shaft Division with the Addition of Newton Motion Fairway Woods Shafts

Retrieved on: 
Thursday, April 4, 2024

CAMARILLO, CA, April 04, 2024 (GLOBE NEWSWIRE) -- Sacks Parente Golf, Inc. (Nasdaq: SPGC) (“SPG” or the “Company”), a technology-forward golf company with a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, expands its product offerings with the newest addition to its Newton Golf Shaft division.

Key Points: 
  • As we unveil the Newton Motion Fairway Woods shaft, we are confident that it will exceed the high expectations set by its driver shaft predecessor.”
    Hand-crafted one-by-one in SPG’s factory in St. Joseph, Missouri, the Newton Motion Fairway Woods shaft is engineered with the same premium materials and advanced technologies that have helped the Newton Motion Driver become a favorite of its early adopters.
  • Designed to deliver longer, straighter shots with less effort, the new fairway woods shaft incorporates Newton Golf’s key technologies:
    Elongated Bend Profile – Optimized for fairway wood shaft lengths, Newton Motion shafts flex over the entire length of the shaft – from grip-to-tip.
  • Newton Golf Shaft’s innovative DOT system, employed by Newton Golf’s expert shaft engineers, optimizes golf shaft performance by fine-tuning it to golfer’s unique abilities, leaving traditional flex systems in the past.
  • The Newton Motion Fairway Woods can be ordered in modern standard #3, #5, or #7 fairway woods lengths.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Retrieved on: 
Wednesday, April 3, 2024

ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.

Key Points: 
  • ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.
  • PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers.
  • PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
  • Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

BON SECOURS MERCY HEALTH AND COMPASS SURGICAL PARTNERS ANNOUNCE GRAND OPENING OF WORLD-CLASS SURGERY CENTER IN GREENVILLE, SOUTH CAROLINA

Retrieved on: 
Tuesday, April 9, 2024

GREENVILLE, S.C. and RALEIGH, N.C., April 9, 2024 /PRNewswire/ -- Millennium Surgery Center, a joint venture between Bon Secours Mercy Health, Compass Surgical Partners (Compass) and local physicians, today announced that it will launch in Greenville, South Carolina, with a grand opening on April 11.

Key Points: 
  • GREENVILLE, S.C. and RALEIGH, N.C., April 9, 2024 /PRNewswire/ -- Millennium Surgery Center, a joint venture between Bon Secours Mercy Health, Compass Surgical Partners (Compass) and local physicians, today announced that it will launch in Greenville, South Carolina, with a grand opening on April 11.
  • Located at 214 Innovation Drive in Greenville, South Carolina, the 20,000-square-foot facility will host a ribbon cutting ceremony on April 11 at 12pm.
  • Millennium Surgery Center expects to secure accreditation from the Accreditation Association for Ambulatory Health Care and certification from Medicare by mid-May.
  • The newly developed facility is the fourth opened thus far through the strategic partnership between Bon Secours Mercy Health and Compass.

Battle Born Brain and Spine Introduces Amplify DualPortal Endoscopic Surgery - Revolutionizing Spine Care in Northern Nevada

Retrieved on: 
Friday, April 5, 2024

CARSON CITY, Nev., April 5, 2024 /PRNewswire-PRWeb/ -- Battle Born Brain and Spine, a leading neurosurgical practice in Northern Nevada, proudly announces the launch of Amplify DualPortal Endoscopic Surgery, the first and only official endoscopic spine surgical practice in the region. This innovative approach to spine surgery is set to revolutionize the way patients receive care for spinal conditions, offering ultra minimally invasive solutions with improved outcomes.

Key Points: 
  • Dr. Sina Rajamand, at Battle Born Brain and Spine in Carson City Nevada, is a leading expert in Endoscopic Spine Surgery, known for his conservative approach and exceptional patient outcomes.
  • CARSON CITY, Nev., April 5, 2024 /PRNewswire-PRWeb/ -- Battle Born Brain and Spine, a leading neurosurgical practice in Northern Nevada , proudly announces the launch of Amplify DualPortal Endoscopic Surgery , the first and only official endoscopic spine surgical practice in the region.
  • The introduction of Amplify Dualportal Endoscopic Surgery further solidifies the practice's reputation as a leader in innovative spine care in the region.
  • For more information about Amplify DualPortal Endoscopic Surgery at Battle Born Brain and Spine, please visit https://www.battlebornbrainandspine.com/ or contact (775) 445-6622.

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Key Points: 


Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene Treatment of aspartylglucosaminuria, 19/10/2020 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene Treatment of aspartylglucosaminuria, 19/10/2020 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene Treatment of aspartylglucosaminuria, 19/10/2020 Withdrawn